Pharmaxis Limited announced the appointment of Dr. Jana Baskar to the role of Chief Medical Officer. Dr. Baskar is a highly experienced executive who has worked in both pharmaceutical and contract research companies. Dr. Jana Baskar has over two decades of experience including overseeing more than 70 phase IIII trials of oncology treatments in his 6 years as Medical Director at Novartis Oncology in Australia.

In his most recent role, he served as Medical Director for IQVIA in Australia and New Zealand where he also co chaired the IQVIA ANZ Oncology Advisory Board providing strategic advice to Biopharma companies. Dr. Baskar received his Bachelor of Medicine degree (MBBS) from the University of Western Australia. He holds a Master of Medical Science in Drug Development from the University of New South Wales, Sydney (MMedSc) and a Masters of Business Administration (MBA) from the Australian Graduate School of Management.

Pharmaxis founding scientist and Medical Director, Dr. Brett Charlton, is retiring after more than 20 years' service with the company during which time he has overseen development programs that lead to two products achieving global regulatory approval and the transition of several pipeline products into clinical development including Pharmaxis' two lead assets in myelofibrosis (PXS5505) and scarring (PXS6302).